H.C. Wainwright lowered the firm’s price target on Delcath Systems to $17 from $19 and keeps a Buy rating on the shares following the Q4 results. With proforma cash of nearly $31M, the company has sufficient funds to run operations through potential approval of Hepzato and commercialization, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DCTH:
- Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
- Delcath Systems reports Q4 EPS (86c), consensus (76c)
- Delcath Systems announces $85M private placement
- Delcath Systems: FDA accepts NDA resubmission for Hepzato Kit
- Delcath Systems, Inc. (DCTH) Q4 Earnings Cheat Sheet
